MedTrace Logo

Assessing the Immunogenicity and Safety of a HIPRA's Candidate Booster Vaccination in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19.

NCT05305573 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2023-03-01

No results posted yet for this study

Summary

Phase IIb clinical trial to assess the Immunogenicity and Safety of a HIPRA's Candidate Booster vaccination (PHH-1V) in adults fully vaccinated with the adenovirus vaccine Vaxevria against COVID-19.

Conditions

  • COVID-19
  • SARS-CoV-2 Acute Respiratory Disease

Interventions

BIOLOGICAL

COVID-19 Vaccine HIPRA 40 ug/dose

Subjects will receive one injection of COVID-19 Vaccine HIPRA (PHH-1V)

BIOLOGICAL

Comirnaty (Pfizer-BioNtech) 30 ug/dose concentrate for dispersion for injection

Subjects will receive one injection of Comirnaty Vaccine

Sponsors & Collaborators

  • Hipra Scientific, S.L.U

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-25
Primary Completion
2022-10-01
Completion
2022-10-01

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05305573 on ClinicalTrials.gov